Erik Muser

1.0k total citations
77 papers, 692 citations indexed

About

Erik Muser is a scholar working on Economics and Econometrics, Psychiatry and Mental health and Genetics. According to data from OpenAlex, Erik Muser has authored 77 papers receiving a total of 692 indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Economics and Econometrics, 22 papers in Psychiatry and Mental health and 21 papers in Genetics. Recurrent topics in Erik Muser's work include Health Systems, Economic Evaluations, Quality of Life (24 papers), Schizophrenia research and treatment (22 papers) and Inflammatory Bowel Disease (21 papers). Erik Muser is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (24 papers), Schizophrenia research and treatment (22 papers) and Inflammatory Bowel Disease (21 papers). Erik Muser collaborates with scholars based in United States, Canada and United Kingdom. Erik Muser's co-authors include Patrick Lefèbvre, Dominic Pilon, Marie‐Hélène Lafeuille, Mei Sheng Duh, Amanda Teeple, Zhijie Ding, Kruti Joshi, John Fastenau, Joseph Menzin and Jacqueline Pesa and has published in prestigious journals such as Journal of Clinical Oncology, Gastroenterology and The Journal of Urology.

In The Last Decade

Erik Muser

75 papers receiving 678 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Erik Muser United States	15	378	142	130	120	120	77	692
Jonathan R. Korn United States	17	118 0.3×	81 0.6×	31 0.2×	99 0.8×	55 0.5×	37	855
Susan Gabriel United States	5	196 0.5×	22 0.2×	19 0.1×	12 0.1×	32 0.3×	10	397
C. Beauchemin Canada	13	171 0.5×	96 0.7×	65 0.5×	92 0.8×	30 0.3×	42	541
David J. Harrison United States	12	60 0.2×	87 0.6×	15 0.1×	25 0.2×	71 0.6×	28	398
André W. Broekmans Netherlands	8	64 0.2×	50 0.4×	35 0.3×	46 0.4×	41 0.3×	15	828
C.F. Chiou United States	8	76 0.2×	48 0.3×	21 0.2×	53 0.4×	72 0.6×	12	478
Evan Kantor United States	10	93 0.2×	166 1.2×	20 0.2×	69 0.6×	53 0.4×	19	796
Kelly P. McCarrier United States	13	76 0.2×	41 0.3×	47 0.4×	83 0.7×	80 0.7×	36	493
Mihaela A. Popa United States	7	112 0.3×	37 0.3×	21 0.2×	21 0.2×	151 1.3×	13	692
Samer Hammoudeh Qatar	11	72 0.2×	10 0.1×	18 0.1×	37 0.3×	36 0.3×	50	410

Countries citing papers authored by Erik Muser

Since Specialization

Citations

This map shows the geographic impact of Erik Muser's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erik Muser with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erik Muser more than expected).

Fields of papers citing papers by Erik Muser

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Erik Muser. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erik Muser. The network helps show where Erik Muser may publish in the future.

Co-authorship network of co-authors of Erik Muser

This figure shows the co-authorship network connecting the top 25 collaborators of Erik Muser. A scholar is included among the top collaborators of Erik Muser based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Erik Muser. Erik Muser is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Karsh, Lawrence I., et al.. (2024). Differences in real‐world outcomes by risk classification for localized prostate cancer patients after radiation therapy. The Prostate. 84(11). 1047–1055. 1 indexed citations

Kaye, Deborah R., Erik Muser, Laura Morrison, et al.. (2024). Real-world economic burden of metastatic castration-resistant prostate cancer before and after first-line therapy initiation. Journal of Medical Economics. 27(1). 201–214. 2 indexed citations

Kaye, Deborah R., Erik Muser, Laura Morrison, et al.. (2024). Characterizing the real-world economic burden of metastatic castration-sensitive prostate cancer in the United States. Journal of Medical Economics. 27(1). 381–391. 2 indexed citations

Lowentritt, Benjamin, Dominic Pilon, Erik Muser, et al.. (2024). Real-world comparison of prostate-specific antigen (PSA) response in patients with metastatic castration-sensitive prostate cancer (mCSPC) treated with apalutamide (APA) or enzalutamide (ENZ).. Journal of Clinical Oncology. 42(4_suppl). 51–51. 1 indexed citations

Kaye, Deborah R., Erik Muser, Laura Morrison, et al.. (2024). Real-world economic burden associated with disease progression from metastatic castration-sensitive to castration-resistant prostate cancer on treatment in the United States. Journal of Managed Care & Specialty Pharmacy. 30(7). 684–697. 2 indexed citations

Bilen, Mehmet Asım, Carmine Rossi, Erik Muser, et al.. (2024). Homologous Recombination Repair Testing Patterns and Outcomes in mCRPC by Alteration Status and Race. ClinicoEconomics and Outcomes Research. Volume 16. 657–674. 1 indexed citations

Bilen, Mehmet Asım, Carmine Rossi, Erik Muser, et al.. (2023). Time-to-next treatment (TTNT) and overall survival (OS) among homologous recombination repair (HRR) positive and HRR negative patients with metastatic castration-resistant prostate cancer (mCRPC) initiating first-line (1L) therapy.. Journal of Clinical Oncology. 41(6_suppl). 80–80. 1 indexed citations

Lowentritt, Benjamin, et al.. (2023). MP29-14 PROSTATE-SPECIFIC ANTIGEN RESPONSE AND TIME-TO-CASTRATION RESISTANCE AMONG PATIENTS WITH METASTATIC CASTRATION SENSITIVE PROSTATE CANCER INITIATED ON APALUTAMIDE, ENZALUTAMIDE, OR ABIRATERONE ACETATE. The Journal of Urology. 209(Supplement 4). 1 indexed citations

Pilon, Dominic, Zhijie Ding, Erik Muser, et al.. (2022). Indicators of Suboptimal Treatment and Associated Healthcare Costs Among Patients With Crohn’s Disease Initiated on Biologic or Conventional Agents. Crohn s & Colitis 360. 4(3). otac021–otac021. 9 indexed citations

10.

Muser, Erik, et al.. (2021). S735 Treatment Patterns Among Crohn’s Disease Patients Initiating Biologics: A Two-Year Pooled Analysis of Three United States Claims Databases. The American Journal of Gastroenterology. 116(1). S337–S338. 1 indexed citations

11.

Lueza, B., et al.. (2020). S0463 Economic Costs Associated With Reduction in Work Productivity Loss for Ulcerative Colitis Patients Receiving Ustekinumab Using Results From the UNIFI Clinical Trial. The American Journal of Gastroenterology. 115(1). S233–S233. 1 indexed citations

12.

Teeple, Amanda, et al.. (2019). Use of the Dermatology Life Quality Index work/study domain to estimate overall work productivity loss among patients with psoriasis: an analysis based on real‐world data. Clinical and Experimental Dermatology. 45(5). 572–575. 5 indexed citations

13.

Teeple, Amanda & Erik Muser. (2018). Cost Per Responder Analysis of Guselkumab Versus Etanercept Using Efficacy Results from Pivotal Clinical Trials in Patients with Moderate to Severe Plaque Psoriasis. Value in Health. 21. S241–S241. 1 indexed citations

14.

Muser, Erik, Chris M Kozma, Carmela Benson, et al.. (2015). Cost effectiveness of paliperidone palmitate versus oral antipsychotics in patients with schizophrenia and a history of criminal justice involvement. Journal of Medical Economics. 18(8). 637–645. 7 indexed citations

15.

Kozma, Chris M, et al.. (2015). Health resource and Criminal Justice system costs for Young Clinical Trial Patients with Schizophrenia and prior Incareration by treatment failure status. Value in Health. 18(3). A122–A122. 1 indexed citations

16.

Kozma, Chris M, Erik Muser, & Carmela Benson. (2014). Baseline health resource and criminal justice system costs for clinical trial patients with schizophrenia and prior incareration. Value in Health. 17(3). A218–A218. 1 indexed citations

17.

Lafeuille, Marie‐Hélène, Judith S. Gravel, Patrick Lefèbvre, et al.. (2013). Patterns of relapse and associated cost burden in schizophrenia patients receiving atypical antipsychotics. Value in Health. 16(3). A60–A60. 1 indexed citations

18.

Edwards, Natalie C., et al.. (2012). The threshold rate of oral atypical anti-psychotic adherence at which paliperidone palmitate is cost saving. Journal of Medical Economics. 15(4). 623–634. 10 indexed citations

19.

Lang, Kathleen, Jonathan R. Korn, Erik Muser, et al.. (2011). Predictors of medication nonadherence and hospitalization in Medicaid patients with bipolar I disorder given long-acting or oral antipsychotics. Journal of Medical Economics. 14(2). 217–226. 31 indexed citations

20.

Durden, Emily, Erin Bagalman, Erik Muser, et al.. (2010). Characteristics, healthcare utilization and costs of bipolar disorder type I patients with and without frequent psychiatric intervention in a Medicaid population. Journal of Medical Economics. 13(4). 698–704. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact